Associations between asymmetric dimethylarginine, homocysteine, and the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism (rs1801133) in rheumatoid arthritis

References

• Martín-Martínez MA, González-Juanatey C, Castañeda S, Llorca J, Ferraz-Amaro I, Fernández-Gutiérrez B, et al. Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: scientific evidence and expert opinion. Semin Arthritis Rheum 2014;44:1–8.
   PubMed Web of Science ®Google Scholar
• Chung CP, Giles JT, Petri M, Szklo M, Post W, Blumenthal RS, et al. Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum 2012;41:535–44.
   PubMed Web of Science ®Google Scholar
• López-Mejías R, García-Bermúdez M, González-Juanatey C, Castañeda S, Miranda-Filloy JA, Gómez-Vaquero C, et al. NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2012;224:426–9.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Rodríguez L, González-Juanatey C, Palomino-Morales R, Vázquez-Rodríguez TR, Miranda-Filloy JA, Fernández-Gutiérrez B, et al. TNFA −308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2011;216:125–30.
   PubMed Web of Science ®Google Scholar
• Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008;121(Suppl 1):S21–31.
   Google Scholar
• Sandoo A, Veldhuijzen van Zanten JJCS, Metsios GS, Carroll D, Kitas GD. Vascular function and morphology in rheumatoid arthritis: a systematic review. Rheumatology 2011;50:2125–39.
   Google Scholar
• Pieringer H, Schumacher S, Stuby U, Biesenbach G. Augmentation index and large-artery remodeling inpatients with longstanding rheumatoid arthritis compared with healthy controls. Semin Artritis Rheum 2009;39:163–9.
   PubMed Web of Science ®Google Scholar
• Sandoo A, Veldhuijzen Van Zanten JJ, Metsios GS, Carroll D, Kitas GD. The endothelium and its role in regulating vascular tone. Open Cardiovasc Med J 2010;4:302–12.
   PubMedGoogle Scholar
• Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009;119:1592–600.
   PubMed Web of Science ®Google Scholar
• Cavusoglu E, Ruwende C, Chopra V, Poludasu S, Yanamadala S, Frishman WH, et al. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis 2010;210:226–31.
   PubMed Web of Science ®Google Scholar
• Leong T, Zylberstein D, Graham I, Lissner L, Ward D, Fogarty J, et al. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol 2008;28:961–7.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113–17.
   PubMed Web of Science ®Google Scholar
• Surdacki A, Martens-Lobenhoffer J, Marewicz E, Rakowski T, Wieczorek-Surdacka E, et al. Elevated plasma asymmetric dimethyl-L-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2007;56:809–19.
   PubMed Web of Science ®Google Scholar
• Sandoo A, Dimitroulas T, Veldhuijzen van Zanten JJ, Smith JP, Metsios GS, Nightingale P, et al. Lack of association between asymmetric dimethylarginine and in vivo microvascular and macrovascular endothelial function in patients with rheumatoid arthritis. Clin Exp Rheumatol 2012;30:388–96.
   Google Scholar
• Dimitroulas T, Sandoo A, Kitas GD. Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases. Int J Mol Sci 2012;13:12315–35.
   PubMed Web of Science ®Google Scholar
• Klimek E, Skalska A, Kwaśny-Krochin B, Surdacki A, Sulicka J, Korkosz M, et al. Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration. Mediators Inflamm 2014;2014:1–11.
   Web of Science ®Google Scholar
• López-Mejias R, Ubilla B, Genre F, Corrales A, Hernández JL, Ferraz-Amaro I, et al. Osteoprotegerin concentrations relate independently to established cardiovascular disease in rheumatoid arthritis. J Rheumatol 2015;42:39–45.
   PubMed Web of Science ®Google Scholar
• López-Mejías R, Corrales A, Genre F, Hernández JL, Ochoa R, Blanco R, et al. Angiopoietin-2 serum levels correlate with severity, early onset and cardiovascular disease in patients with rheumatoid arthritis. Clin Exp Rheumatol 2013;31:761–6.
   PubMed Web of Science ®Google Scholar
• Boers GH. Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease. Semin Thromb Hemost 2000;26:291–5.
   PubMed Web of Science ®Google Scholar
• Refai TM, Al-Salem IH, Nkansa-Dwamena D, Al-Salem MH. Hyperhomocysteinaemia and risk of thrombosis in systemic lupus erythematosus patients. Clin Rheumatol 2002;21:457–61.
   PubMed Web of Science ®Google Scholar
• Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001;73:613–21.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Rodríguez L, López-Mejías R, García-Bermúdez M, González-Juanatey C, González-Gay MA, Martín J. Genetic markers of cardiovascular disease in rheumatoid arthritis. Mediators Inflamm 2012;2012:574817.
   PubMedGoogle Scholar
• Dunn J, Title LM, Bata I, Johnstone DE, Kirkland SA, O’Neill BJ, et al. Relation of a common mutation in methylenetetrahydrofolate reductase to plasma homocysteine and early onset coronary artery disease. Clin Biochem 1998;31:95–100.
   PubMed Web of Science ®Google Scholar
• Xin XY, Song YY, Ma JF, Fan CN, Ding JQ, Yang GY, et al. Gene polymorphisms and risk of adult early-onset ischemic stroke: a meta-analysis. Thromb Res 2009;124:619–24.
   PubMed Web of Science ®Google Scholar
• Khandanpour N, Willis G, Meyer FJ, Armon MP, Loke YK, Wright AJ, et al. Peripheral arterial disease and methylenetetrahydrofolate reductase (MTHFR) C677T mutations: a case-control study and meta-analysis. J Vasc Surg 2009;49:711–18.
   PubMed Web of Science ®Google Scholar
• Clarke R, Bennett DA, Parish S, Verhoef P, Dötsch-Klerk M, Lathrop M, et al. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med 2012;9:e1001177.
   Google Scholar
• Nakai K, Itoh C, Nakai K, Habano W, Gurwitz D. Correlation between C677T MTHFR gene polymorphism, plasma homocysteine levels and the incidence of CAD. Am J Cardiovasc Drugs 2001;1:353–61.
   PubMedGoogle Scholar
• Holmes MV, Newcombe P, Hubacek JA, Sofat R, Ricketts SL, Cooper J, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 2011;378:584–94.
   PubMed Web of Science ®Google Scholar
• Dayal S, Lentz SR. ADMA and hyperhomocysteinemia. Vasc Med 2005;10(Suppl 1):S27–33.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–19.
   PubMed Web of Science ®Google Scholar
• Palomino-Morales R, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Rodriguez L, Miranda-Filloy JA, Fernandez-Gutierrez B, et al. A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. Arthritis Res Ther 2010;12:R71.
   Google Scholar
• Davis LA, Cannon GW, Pointer LF, Haverhals LM, Wolff RK, Mikuls TR, et al. Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis. J Rheumatol 2013;40:809–17.
   PubMed Web of Science ®Google Scholar
• Franceschelli S, Ferrone A, Pesce M, Riccioni G, Speranza L. Biological functional relevance of asymmetric dimethylarginine (ADMA) in cardiovascular disease. Int J Mol Sci 2013;14:24412–21.
   PubMed Web of Science ®Google Scholar
• Karbach S, Wenzel P, Waisman A, Munzel T, Daiber A. eNOS uncoupling in cardiovascular diseases – the role of oxidative stress and inflammation. Curr Pharm Des 2014;20:3579–94.
   PubMed Web of Science ®Google Scholar
• Chobanyan-Jürgens K, Pham VV, Stichtenoth DO, Tsikas D. Elevated dimethylarginine dimethylaminohydrolase (DDAH) activity in rheumatoid arthritis and spondyloarthritis. Nitric Oxide 2011;25:436–8.
   PubMed Web of Science ®Google Scholar
• Włoch A, Wieczorek-Surdacka E, Sulicka-Grodzicka J, Kruszelnicka O, Surdacki A. Asymmetric dimethylarginine reflects cumulative inflammatory burden in rheumatoid arthritis. Rheumatology 2015;54:1135–6.
   PubMed Web of Science ®Google Scholar
• Dimitroulas T, Sandoo A, Veldhuijzen van Zanten JJ, Smith JP, Hodson J, Metsios GS, et al. Predictors of asymmetric dimethylarginine levels in patients with rheumatoid arthritis: the role of insulin resistance. Scand J Rheumatol 2013;42:176–81.
   Google Scholar
• Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001;104:2569–75.
   PubMed Web of Science ®Google Scholar
• Liu LH, Guo Z, Feng M, Wu ZZ, He ZM, Xiong Y. Protection of DDAH2 overexpression against homocysteine-induced impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells. Cell Physiol Biochem 2012;30:1413–22.
   PubMed Web of Science ®Google Scholar
• Böger RH, Lentz SR, Bode-Böger SM, Knapp HR, Haynes WG. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) 2001;100:161–7.
   PubMed Web of Science ®Google Scholar
• Doshi S, McDowell I, Goodfellow J, Stabler S, Boger R, Allen R, et al. Relationship between S-adenosylmethionine, S-adenosylhomocysteine, asymmetric dimethylarginine, and endothelial function in healthy human subjects during experimental hyper- and hypohomocysteinemia. Metabolism 2005;54:351–60.
   PubMed Web of Science ®Google Scholar
• Kayacelebi AA, Willers J, Pham VV, Hahn A, Schneider JY, Rothmann S, et al. Plasma homoarginine, arginine, asymmetric dimethylarginine and total homocysteine interrelationships in rheumatoid arthritis, coronary artery disease and peripheral artery occlusion disease. Amino Acids 2015;47:1885–91.
   PubMed Web of Science ®Google Scholar
• Lopez-Olivo MA, Gonzalez-Lopez L, Garcia-Gonzalez L, Villa-Manzano AI, Cota-Sanchez AR, Salazar-Paramo MA, et al. Factors associated with hyperhomocysteinaemia in Mexican patients with rheumatoid arthritis. Scand J Rheumatol 2006;35:112–16.
   PubMed Web of Science ®Google Scholar
• Wållberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapää-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002;29:875–82.
   PubMed Web of Science ®Google Scholar
• Willers J, Hahn A. Cardiovascular risk in patients with rheumatoid arthritis: assessment of several traditional risk parameters and a German risk score model. Rheumatol Int 2012;32:3741–9.
   PubMed Web of Science ®Google Scholar
• Lazzerini PE, Capecchi PL, Selvi E, Lorenzini S, Bisogno S, Galeazzi M, et al. Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev 2007;6:503–9.
   PubMed Web of Science ®Google Scholar
• Sandoo A, Dimitroulas T, Hodson J, Smith JP, Douglas KM, Kitas GD. Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study. Rheumatology 2015;54:1145–52.
   PubMed Web of Science ®Google Scholar
• Cáliz R, del Amo J, Balsa A, Blanco F, Silva L, Sanmarti R, et al. The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population. Scand J Rheumatol 2012;41:10–14.
   PubMed Web of Science ®Google Scholar
• Böger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000;87:99–105.
   PubMed Web of Science ®Google Scholar
• Wasko MC, Dasgupta A, Hubert H, Fries JF, Ward MM. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum 2013;65:334–42.
   PubMed Web of Science ®Google Scholar